Lv1
50 积分 2022-09-23 加入
Methods for Adjusting for Bias Due to Crossover in Oncology Trials
2天前
已完结
Treatment of Pleural Mesothelioma: ASCO Guideline Update
22天前
已完结
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights
25天前
已完结
Treatment of Pleural Mesothelioma: ASCO Guideline Update
25天前
已完结
Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data
25天前
已完结
Global magnitude and temporal trend of mesothelioma burden along with the contribution of occupational asbestos exposure in 204 countries and territories from 1990 to 2019: Results from the Global Burden of Disease Study 2019
25天前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
3个月前
已完结
Ponsegromab for the Treatment of Cancer Cachexia
3个月前
已完结
Pembrolizumab in HER2-Positive Gastric Cancer
3个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
3个月前
已完结
皖公网安备34019202002308
